A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

This study has been completed.

Study NCT00051597 Information provided by Seattle Genetics, Inc.

First Received: January 13, 2003 Last Updated: October 7, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	August 2003
Estimated Primary Completion Date:	No date given